Convatec Announces $1 Billion Investment in R&D Facilities Across US and UK

Convatec, a leading provider of medical devices for chronic conditions, has unveiled plans to invest over $1 billion in research and development facilities in the United States and United Kingdom over the next decade. This significant commitment aims to bolster the company's innovation capabilities and strengthen its position in key markets.

US Expansion: $600 Million Boost for Boston R&D Hub

As part of its 10-year investment strategy, Convatec has earmarked $600 million for its US operations, with a primary focus on expanding its Boston research facility. The company plans to increase capacity at the Boston site by 50%, enhancing laboratory, testing, and collaboration spaces. This expansion is expected to be completed by the end of 2025, reinforcing Convatec's presence in its largest commercial market.

Currently, more than 10% of Convatec's 10,000 global employees are based in the United States, with the company actively growing its US workforce. The Boston investment is poised to create additional job opportunities and further cement Convatec's commitment to innovation in medical devices.

UK Investment: $650 Million for New Manchester R&D Center

In a parallel move, Convatec is investing $650 million to relocate its UK R&D operations from Deeside, North Wales, to a new state-of-the-art facility in Manchester. The new center, scheduled to open in 2027, will be strategically located at a major hospital, facilitating collaboration with leading universities, hospitals, and research institutions in the area.

The company plans to transfer approximately 200 employees from Deeside to Manchester, while maintaining its manufacturing operations in Wales with around 400 staff. This relocation represents a significant shift in Convatec's R&D footprint, as the Deeside site has been a major research center for the company since 1996.

Strategic Positioning and Market Outlook

Convatec's investment strategy comes at a time when the company is experiencing growth across its business units. In 2024, the company reported revenues of $2.3 billion, with North America accounting for 56% of sales in the first half of 2025. Convatec currently holds leading positions in several key markets, including:

• Global leader in disposable infusion sets
• Top provider of urinary continence products and services in the US
• Third-largest player in global advanced wound and ostomy care markets

The company's confidence in the UK market is evident, despite ongoing challenges in the pharmaceutical industry. Convatec stated that its plans "reflect our confidence in the UK's future as a global hub," while acknowledging the importance of supportive government policies, legislation, and reimbursement decisions for its operations.

As Convatec moves forward with these significant investments, the medical device industry will be watching closely to see how these expanded R&D capabilities translate into innovative products and market growth in the coming years.